Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Jun. 2025,
Tissue Regenix Group paid€0.00 Mil more to buy back shares than it received from issuing new shares.
It received€0.48 Mil from issuing more debt.
It paid€0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received€0.00 Mil from paying cash dividends to shareholders.
It spent€0.45 Mil on other financial activities.
In all, Tissue Regenix Groupearned€0.04 Mil on financial activities for the
six
months ended in Jun. 2025.
Tissue Regenix Group (FRA:LSW) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Tissue Regenix Group's issuance of stock for the
six
months ended in Jun. 2025 was €0.00 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Tissue Regenix Group's repurchase of stock for the
six
months ended in Jun. 2025 was €0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Tissue Regenix Group's net issuance of debt for the
six
months ended in Jun. 2025 was €0.48 Mil.
Tissue Regenix Group received€0.48 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Tissue Regenix Group's net issuance of preferred for the
six
months ended in Jun. 2025 was €0.00 Mil.
Tissue Regenix Group paid€0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Tissue Regenix Group's cash flow for dividends for the
six
months ended in Jun. 2025 was €0.00 Mil.
Tissue Regenix Group received€0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Tissue Regenix Group's other financing for the
six
months ended in Jun. 2025 was €-0.45 Mil.
Tissue Regenix Group spent€0.45 Mil on other financial activities.
Tissue Regenix Group Cash Flow from Financing Related Terms
Tissue Regenix Group Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Tissue Regenix Group's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tissue Regenix Group Cash Flow from Financing Chart
Tissue Regenix Group Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Tissue Regenix Group's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €2.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of €2.41 Mil mean?
Tissue Regenix Group (FRA:LSW) has a Cash Flow from Financing of €2.41 Mil as of Jun. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Tissue Regenix Group and its competitors.
Is Tissue Regenix Group's Cash Flow from Financing too high?
Tissue Regenix Group's current Cash Flow from Financing is €2.41 Mil. Overall, Tissue Regenix Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tissue Regenix Group's Cash Flow from Financing compare to VRTX and REGN?
Tissue Regenix Group's Cash Flow from Financing of €2.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Biotechnology company?
A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Tissue Regenix Group and its competitors. Tissue Regenix Group's current Cash Flow from Financing is €2.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (FRA:LSW) has a current Cash Flow from Financing of €2.41 Mil. The stock's GF Value™ is €0.84, compared to a current price of €0.07 — trading 91.7% below its estimated fair value. The current Cash Flow from Financing is €2.41 Mil. Tissue Regenix Group's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Tissue Regenix Group (FRA:LSW), the current Cash Flow from Financing is €2.41 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tissue Regenix Group (FRA:LSW) Overvalued in 2026?
Based on GuruFocus' analysis, Tissue Regenix Group stock appears to be undervalued.
The current stock price of €0.07 is trading 91.7% below its estimated GF Value™ of €0.84.
Key valuation signals for FRA:LSW:
Cash Flow from Financing: €2.41 Mil
GF Value™: €0.84 vs. price of €0.07 (91.7% below fair value)
No single metric tells the full story. See the FRA:LSW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
10GF Score
Get the complete analysis for FRA:LSW
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LSW has been successfully added to your 
